only drug against 5-LOX, was withdrawn from the market due to several problems. In the present study, the performance of rationally designed conjugates of thiazole (2) and thiourea (3) scaffolds from our previously reported 2-amino-4-aryl thiazole (1) is reported. They are synthesized (total 31 derivatives), characterized, and tested against the 5-LOX enzyme in vitro and the mode of action of the most
人5-脂
氧合酶(5-LOX)是针对哮喘和炎症的关键酶。Zileuton是唯一一种针对5-LOX的药物,由于几个问题而退出市场。在本研究中,报道了我们先前报道的2-
氨基-4-芳基
噻唑(1)对
噻唑(2)和
硫脲(3)支架进行合理设计的偶联物的性能。它们是合成的(总共31个衍
生物),在体外进行了表征并针对5-LOX酶进行了测试,并确定了活性最高的酶的作用方式。化合物2m的IC 500.9±0.1μM的化合物通过竞争性(非
氧化还原)机理起作用,与Zileuton不同,它没有自由基清除性能。计算研究与支持其作用机理的实验数据非常吻合。来自
硫脲系列(3)的另一个
铅分子3f对5-LOX的IC 50为1.4±0.1μM,其作用方式为
氧化还原类型(非竞争性)。有希望地注意到,
铅抑制剂2m和3f表现出的活性均优于商品药物Zileuton(IC 50 = 1.5 ± 0.3μM)。这些
抑制剂可以进一步发展为抗炎药。